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RESUMO 
 
A terapia anticoagulante oral é amplamente utilizada para a prevenção primária de 
eventos tromboembólicos em indivíduos com fibrilação atrial e próteses valvares. O 
tratamento de pacientes anticoagulados que necessitam de procedimentos odontológicos 
cirúrgicos é variado e controverso devido à discussão sobre a possibilidade de 
hemorragia não controlada ou de complicações tromboembólicas. Atualmente, o ácido 
tranexâmico (ATX) administrado de forma intravenosa tem se mostrado eficaz no 
controle de sangramento em diversos tipos de cirurgias. Entretanto, até o momento, não 
há evidências sobre a eficácia e segurança do ATX tópico na redução de sangramento 
de pacientes anticoagulados submetidos a procedimentos cirúrgicos, incluindo as 
cirurgias orais de pequeno porte. O objetivo desta revisão sistemática com meta-análise 
é investigar a eficácia e a segurança do ATX tópico no controle do sangramento pós-
operatório em pacientes anticoagulados submetidos à cirurgia oral menor. Uma busca 
sistemática no PubMed, SCOPUS, Cochrane Central Register of Controlled Trials 
(CENTRAL), OpenThesis e banco de dados internacional para ensaios clínicos 
(clinicaltrials.gov) até maio de 2015 foi realizada. Uma pesquisa na literatura-cinza foi 
feita através do Google Scholar. A revisão foi restrita a estudos publicados em versões 
de texto completo, sem restrição de idioma. Dois revisores de forma independente 
rastrearam os resultados da busca e identificaram os ensaios clínicos que compararam o 
uso de ATX tópico versus outro agente hemostático tópico, placebo ou a interrupção / 
redução da terapia anticoagulante antes da cirurgia. Os defechos pré-definidos incluiram 
o sangramento dentro da primeira semana de pós-operatório com necessidade de 
intervenção clínica e eventos tromboembólicos. O risco de viés foi avaliado de acordo 
com as diretrizes da Cochrane para os ensaios clínicos. O risco relativo (RR) foi 
calculado para avaliar o efeito da aplicação tópica de ATX no controle da hemorragia 
pós-operatória. Heterogeneidade estatística foi analisado pelo teste Q de Cochran e 
índice de I2. Para examinar o potencial viés de publicação, foi criado um funnel plot das 
estimativas individuais, em unidades logarítmicas, contra o erro padrão. Após triagem 
dos títulos e resumos, 21 artigos foram lidos na íntegra e 7 ensaios clínicos foram 
incluídos na meta-análise (totalizando 533 pacientes). O RR combinado para o número 
de pacientes que receberam ATX tópico em comparação com o grupo controle foi de 
0,42 (95% IC 0,21 a 0,84; p = 0,01), indicando um efeito protetor do ATX sobre o 
sangramento após cirurgia oral menor. Uma moderada heterogeneidade entre os estudos 
foi observada (I2 = 26%), a qual desapareceu (I2 = 0%) após análise de subgrupo para as 
diferentes estratégias utilizadas nos grupos controle. A análise de subgrupos revelou que 
o ATX tópico foi eficaz na prevenção de sangramento pós-operatório em comparação 
ao placebo (RR = 0,09; IC de 95%: 0,02 a 0,48; p = 0,004) e ácido épsilon-
aminocapróico (RR = 0,12, IC 95% 0,01 a 0,94; p = 0,04). No entanto, nenhuma 
diferença significativa foi observada nas outras análises. Não houve casos de eventos 
tromboembólicos em nenhum estudo, tanto no grupo do ATX quanto no controle, 
durante os primeiros sete dias de acompanhamento. Os dados disponíveis sugerem que a 
irrigação do sítio cirúrgico seguido por bochechos com ATX reduz o risco de 
sangramento, na primeira semana de pós-operatório, em cirurgia oral menor de 
pacientes anticoagulados. No entanto, ensaios clínicos adicionais devem ser realizados 
para comparar a eficácia do ATX em relação aos agentes hemostáticos absorvíveis. 
 
Palavras-Chaves: Ácido tranexâmico; Cirurgia bucal; Hemorragia; Hemostasia 
Cirúrgica. 
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ABSTRACT 
 
 
Oral anticoagulants are widely used for primary prevention of thromboembolic 
events in patients with atrial fibrillation and prosthetic heart valves. The treatment of 
patients under OAT who need oral surgery procedures is varied and controversial due to 
the discussion on the uncontrolled bleeding and the possibility of thromboembolic 
complications. Currently, intravenous tranexamic acid (TXA) has been proven to be 
effective in preventing bleeding in several types of surgery, including orthognathic 
surgery. To the best of our knowledge, there is no evidence on the efficacy and safety of 
topical TXA in reducing blood loss in anticoagulated patients undergoing minor oral 
surgery procedures. The aim of this systematic review with meta-analysis is to 
investigate the efficacy and safety of topical TXA to prevent postoperative bleeding in 
anticoagulated patients undergoing minor oral surgery. A systematic search in PubMed, 
SCOPUS, Cochrane Central Register of Controlled Trials (CENTRAL), OpenThesis 
and international database for clinical trials from inception to May 2015 was done. A 
grey-literature search was conducted through Google Scholar. Our search was restricted 
to studies published in full-text versions, without language restriction. Two reviewers 
independently screened the search results and identified clinical trials that compared the 
use of topical TXA versus other topical hemostatic agent, placebo or 
interruption/decrease of anticoagulant therapy prior to the surgery. Our predefined 
outcomes were bleeding within the first postoperative week with need for clinical 
intervention and thromboembolic events. The risk of bias was assessed according to the 
Cochrane guidelines for clinical trials. The pooled relative risk (RR) was calculated for 
the effect of topical application of TXA on postsurgical bleeding. Statistical 
heterogeneity was assessed using the Cochran Q test and quantified by the I2 index. To 
assess potential publication bias we created a funnel plot by plotting the individual 
estimates in log units against the standard error. After screening titles and abstracts, 21 
full-text articles were assessed for eligibility and 7 clinical trials were included in the 
final analysis (a total of 533 patients). The combined RR for the number of patients 
receiving TXA in comparison to the control group was 0.42 (95% CI 0.21 to 0.84; p = 
0.01), indicating a protective effect of topical TXA on bleeding after minor oral 
surgeries. A moderate between-study heterogeneity was observed (I2 = 26%) that 
disappeared (I2 = 0%) after subgroup analysis by different strategies used in the control 
groups. Subgroup analysis revealed that topical TXA was effective to prevent 
postsurgical bleeding compared to placebo (RR = 0.09; 95% CI 0.02 to 0.48; p = 0.004) 
and epsilon-aminocaproic acid (RR = 0.12; 95% CI 0.01 to 0.94; p = 0.04). However, 
no significant difference was observed in other analysis. There were no cases of 
thromboembolic events in any study, in either the TXA or the control groups, during the 
one to 7 day follow-up period after surgery. Available data suggest that irrigation of 
surgical site with TXA followed by mouthwash during the first postoperative week can 
reduce the risk of bleeding after minor oral surgeries in anticoagulated patients. 
However, additional trials should be conducted to compare TXA efficacy over 
absorbable hemostatic materials. 
 
 
Key words: Tranexamic acid; Oral surgery; Hemorrhage. 
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1) INTRODUÇÃO 
 
 Os anticoagulantes orais são drogas comumente prescritas para prevenção primária de 
eventos tromboembólicos na fibrilação atrial e em pacientes com próteses cardíacas, bem 
como na prevenção secundária após embolismo sistêmico em pacientes com doenças 
reumáticas da valva mitral, prolapso da valva mitral, calcificação anular mitral, regurgitação 
mitral não reumática e ateromas aórticos móveis ou placas aórticas maiores do que 4 mm 
(SCHULMAN, 2003).  
A maior desvantagem do uso de anticoagulantes orais é o aumento do risco de 
hemorragias após injúrias traumáticas e procedimentos cirúrgicos. Na maioria das vezes são 
administrados em pacientes idosos, onde a demanda para procedimentos de exodontia é mais 
elevada (BROEKEMA et al., 2014) e o risco de sangramento pós-operatório é significante 
(KÄMMERER et al., 2014). Desta forma, esses pacientes estão mais susceptivéis a sofrer 
uma hemorragia indesejável (BATISTA, 2010), bem como trismos ou obstrução de vias 
aéreas superiores por consequências de  grandes hematomas (BUMP,  KOLODNY, 1973). 
Os agentes anticoagulantes orais mais utilizados são os inibidores da agregação 
plaquetária (ácido acetilsalisílico e clopidogrel) e antagonistas da vitamina K (varfarina, 
acenocumarol e feprocumon) (BROEKEMA et al., 2014).  A varfarina, por ter indicação em 
múltiplas situações - como a fibrilação atrial e tromboembolismo venoso, é o fármaco 
anticoagulante oral mais utilizado (AMERICAN HEART ASSOCIATION, 2001). 
Habitualmente, esta medicação é administrada para prevenção de manifestações 
tromboembólicas, e reduz o risco de eventos trombólicos arteriais em 70% e 
tromboembolismo venoso recorrente em 90% (NEMATULLAH et al., 2009). Todavia, deve-
se ter atenção especial quando o paciente necessita de intervenção cirúrgica, já que sua 
suspensão pode acarretar em aumento do risco de tromboembolismo e sua não remoção pode 
gerar um quadro de hemorragia pós-operatória de difícil controle e de grande repercussão 
(SOUTO et al., 1996). 
 Na literatura ainda não existe um consenso geral sobre a conduta pré- e trans- 
operatória mais adequada para pacientes anticoagulados, principalmente no caso de uso 
prolongado de varfarina. No passado, a prática de suspensão do uso de anticoagulante oral era 
rotineira, sendo proposta por diversos autores, por alguns dias antes do procedimento 
cirúrgico (BLINDER et al., 1999), o que acarreta um maior risco de tromboembolismo para o 
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paciente. Garcia et al. (2008) realizaram um estudo prospectivo do efeito da interrupção de 
varfarina por 5 dias antes de vários procedimentos cirúrgicos de pequeno porte. Os autores 
concluíram que esta interrupção está associada com um risco 0,7% de tromboembolismo e um 
risco ainda mais elevado de episódios de sangramento clínicos significativos (1,7%). Desta 
forma, a interrupção da terapia anticoagulante, em especial a varfarina, pode aumentar o risco 
de tromboembolismo, como o acidente vascular cerebral, o qual pode estar associado com a 
mortalidade e morbidade de longo prazo (LONGSTRETH et al., 2001). 
  Entretanto, nos últimos anos, a continuação da terapia anticoagulante nos casos de 
cirurgias orais menores tem se destacado, principalmente em associação a um agente 
hemostático local (CARTER, GOSS, 2003). Assim, o regime de anticoagulante oral 
permanece inalterado e o paciente deve ser tratado com várias medidas hemostáticas locais 
incluindo o uso de esponjas de colágeno, celulose oxidada, cola de fibrina, suturas e ácido 
tranexâmico para reduzir o risco de hemorragia (SINDET-PEDERSEN et al., 1989; 
BERNADONI SOCORRO et al.,1998; BLINDER et al., 1999; CARTER et al., 2003; BACCI 
et al., 2010). 
O ácido tranexâmico é classificado como um agente anti-fibrinolítico, análogo de 
lisina, que forma um complexo reversível com o plasminogênio e a plasmina (CARTER et al., 
2003; GANDA, 2013). Ao bloquear competitivamente a conversão de plasminogênio em 
plasmina, esta ligação inibe a ação proteolítica da plasmina no coágulo de fibrina e receptores 
de plaquetas, de modo a inibir a fibrinólise na ferida cirúrgica (DUNN, GOA, 1999; Mc 
CORMACK, 2012; SONG et al., 2013). 
A vantagem evidente da inibição local da fibrinólise em pacientes anticoagulados é a 
simplicidade e eficácia do tratamento combinado com a ausência de efeitos secundários 
graves. Uma vez que a terapia anticoagulante não é descontinuada, o paciente não é exposto a 
potenciais complicações, tais como tromboembolismo e suas consequências (KEARON, 
HIRSCH, 1997). A hemostasia pode ser alcançada rapidamente e com segurança sem o risco 
de complicações maiores (CARTER et al., 2003). 
Uma série de revisões sistemáticas com meta-análises foram publicadas demonstrando 
forte evidência de que a administração do ácido tranexâmico reduz o sangramento e a 
necessidade de transfusão sanguínea em artroplastias de joelho (YU et al., 2015; GANDHI et 
al., 2013), cirurgias de quadril (XU et al., 2015; WEI, LIU, 2015; GHADHI et al., 2013) e da 
coluna vertebral (CHERIYAN et al., 2015; ZHANG et al., 2014), sem aumento do risco de 
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complicações tromboembólicas incluindo infarto do miocárdio, trombose venosa profunda e 
embolia pulmonar.  
Resultados semelhantes foram observados por Song et al. (2013) e Olsen et al. (2015) 
após a realização de revisão sistemática com meta-análise para avaliação da eficácia do ácido 
tranexâmico sobre a redução da perda de sangue em pacientes hígidos submetidos à cirurgia 
ortognática. Em ambos os estudos, os autores sugeriram a administração intravenosa de ácido 
tranexâmico para controle de sangramento intraoperatório, mas indicaram a necessidade de 
estudos a respeito da eficácia do medicamento em sua forma tópica. Até o momento, não 
existem revisões sistemáticas com meta-análise para avaliação da eficácia e segurança do 
ácido tranexâmico tópico na redução do sangramento em pacientes sob terapia anticoagulante 
oral submetidos a procedimentos de cirurgia oral menor, muito comuns na prática 
odontológica.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11 
 
 
2) OBJETIVO 
- Avaliar, através de uma revisão sistemática com meta-análise, a eficácia do uso tópico 
de ácido tranexâmico na redução do risco de sangramento pós-operatório e sua segurança em 
relação a complicações tromboembólicas em pacientes em uso de terapia anticoagulante e são 
submetidos a procedimentos de cirurgia oral menor sem alteração do protocolo do fármaco 
anticoagulante. 
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3) MATERIAL E MÉTODOS 
Esta revisão sistemática e meta-análise foi conduzida de acordo com o modelo 
PRISMA (Preferred ReportingItems for Systematic Reviewsand Meta-Analyses) (MOHER, 
2010) e suplementada pelo Manual da Cochrane Collaboration (HIGGINS et al., 2011). Um 
protocolo de revisão sistemática foi concebido a priori e registrado na base de registro de 
revisões sistemáticas PROSPERO (número de registro CRD 42014013072). 
 
3.1) Estratégia de busca 
Foram utilizadas as bases de dados eletrônicas PubMed, SCOPUS, Cochrane Central 
Register of Controlled Trials (CENTRAL), OpenThesis (www.openthesis.org), além do 
Google Acadêmico e a base de dados internacional para ensaios clínicos 
(www.clinicaltrials.gov) até maio de 2015. Nossa busca foi restrita a estudos na íntegra, em 
sua versão completa, sem restrições de língua. A lista de referências de todos os estudos 
elegíveis e revisados foi manualmente analisada para identificação de estudos adicionais a 
serem incluídos. 
Os termos de busca incluíram “tranexamic acid”, “oral surgery”, “oral surgical 
procedures”, “dental extraction”, “toothextraction”, “third molar”, “anticoagulants”, “oral 
hemorrhage”, “hemorrhage”, “oral hemorrhage”, e “bloodloss”.  
A estratégia de busca foi estruturada utilizando os seguintes termos: ((“tranexamic 
acid”) AND (“oral surgery” OR “oral surgical procedures” OR“dental extraction” OR “tooth 
extraction” OR“third molar”) AND (“oral hemorrhage” OR “hemorrhage” OR “blood loss”)). 
Para o banco de dados OpenThesis, os termos de pesquisa foram (“tranexamic acid” AND 
“oral surgery”). Não foram realizados filtros durante a busca, para ampliar o número de 
artigos elegíveis. 
 
3.2) Critérios de elegibilidade e seleção dos estudos 
 Dois autores (PRSM-F e SJAV), de forma independente, analisaram os estudos para 
possível inclusão seguindo os seguintes critérios de elegibilidade. Divergências entre os 
autores foram resolvidas em consenso ou por um terceiro revisor (TSS): 
População: pacientes anticoagulados submetidos à cirurgia oral menor, independente 
do tipo de procedimento cirúrgico. 
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Grupo de Intervenção e Controle:  uso tópico de ácido tranexâmico por pelo menos 
48 horas após a cirurgia versus outro agente local hemostático, placebo (solução inócua) ou 
interrupção/diminuição da dose da terapia anticoagulante. 
Desfecho: sangramento na primeira semana de pós-operatório com necessidade de 
intervenção e eventos tromboembólicos clínicos (infarto do miocárdio, acidente vascular 
cerebral, embolia sistêmica, trombose de uma válvula cardíaca mecânica, trombose da câmara 
cardíaca, trombose venosa profunda ou embolia pulmonar). Os estudos elencados deveriam 
relatar pelo menos o número de pacientes ou sítios cirúrgicos com sangramento pós-
operatório como desfecho. 
Desenho do Estudo: ensaios clínicos (ECs) que avaliassem que uso do ácido 
tranexâmico no sangramento pós-operatórios de cirurgias orais menores.  
Estudos com pacientes apresentando RNI (Razão Normalizada Internacional) ou 
outros parâmetros de coagulação do sangue dentro do padrão de normalidade no período pré-
operatório ou com anormalidades de coagulação, incluindo hemofilia, transplantados 
hepáticos e doença hepática, foram excluídos. Além disso, nós excluimos estudos usando 
ácido tranexâmico em pacientes saudáveis e estudos utilizando ácido tranexâmico intravenoso 
na perda sanguínea em procedimentos de cirurgia oral. 
 
3.3) Extração dos dados e avaliação do risco de viés 
Usando uma folha padronizada de coleta de dados (apêndice A), foram extraídas as 
seguintes informações: autores, ano de publicação, tipo do estudo, características 
demográficas dos participantes do estudo, tipo de cirurgia, tipo patologia e anticoagulante 
oral, a dose e o tempo de ácido tranexâmico, grupo controle, período de acompanhamento 
pós-operatório, número de sítios cirúrgicos ou pacientes com sangramento pós-operatório. 
O risco de viés foi avaliado de acordo com as diretrizes da Cochrane para ensaios 
clínicos. Foram avaliados sete domínios de avaliação: geração de sequência aleatória e 
ocultação de alocação (viés de seleção), cegamento dos participantes e profissionais (viés de 
performance) ou não, cegamento de avaliação do desfecho (viés de detecção), desfechos 
incompletos (viés de atrito), relato de desfecho seletivo (viés de relato), e outras fontes 
potenciais de viés. O risco de viés foi avaliado como sendo baixo, incerto ou alto de acordo 
com critérios estabelecidos (HIGGINS et al., 2011). 
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3.4) Medidas de tratamento, síntese de dados e qualidade da evidência 
O risco relativo resumido foi calculado para o efeito da aplicação tópica do ácido 
tranexâmico no sangramento pós-cirúrgico. Um forest plot foi usado para apresentar 
graficamente o tamanho do efeito e o intervalo de confiança (IC) de 95%. Cada estudo foi 
representado por um quadrado no gráfico, sendo este proporcional ao peso do estudo na meta- 
análise. Valores de p<0,05 para duas caudas foi utilizado para determinar significância 
estatística. 
 A variabilidade entre os estudos foi avaliada usando o teste Q (COCHRAN, 1954) e 
quantificada pelo índice I  (HIGGINS e THOMPSON, 2002). Índices menores do que 25% 
indicaram baixa heterogeneidade entre os estudos, entre 25 e 75% moderada heterogeneidade 
e acima de 75% alta heterogeneidade (HIGGINS, THOMPSON, 2002). Na presença de 
moderada ou alta heterogeneidade, as estimativas reunidas e o IC de 95% correspondente 
foram calculadas com base no modelo de efeitos aleatórios utilizando o método DerSimonian-
Laird. Em caso de baixa heterogeneidade, um modelo de efeitos fixos foi utilizado.  
No modelo de efeitos aleatórios de meta-análise, o risco para os estudos individuais foi 
assumido a variar em torno do tamanho do efeito combinado (BORENSTEIN, 2010). 
Possíveis fontes de heterogeneidade foram analisadas: (1) critérios utilizados para mensuração 
de sangramento pós-operatório, (2) associação de outro agente local hemostático e (3) o 
método de aplicação tópica de ácido tranexâmico. A análise dos subgrupos de acordo com as 
possíveis fontes de heterogeneidade também foi realizada. 
Para avaliar a presença de viés de publicação, um gráfico de funnel plot foi criado para 
as estimativas individuais em unidades logaritmicas versus o erro padrão. Para avaliar o viés 
de publicação, foi analisado visualmente o perfil de simetria do gráfico, com posterior teste de 
Begg e Mazumbar com continuidade de correção (BEGG  e MAZUMDAR, 1994). Os 
estudos maiores e mais precisos encontram-se na parte superior do gráfico, próximo à medida 
de efeito combinada, indicada pela linha ortogonal. Já os estudos considerados menores e 
menos precisos estão espalhados em ambos os lados da linha. No caso de distribuição 
simétrica dos estudos, não há evidência de viés de publicação. A análise de sensibilidade 
"leave-one-out" foi realizada omitindo um estudo de cada vez e analisando a influência de 
cada estudo individual no tamanho efeito combinado (STERNE , EGGER e SMITH, 2001). 
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Todas as análises foram conduzidas utilizando o programa Review Manager 5.3 (Cochrane 
IMS, Copenhagen, Denmark). 
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Abstract 
 
 
Background: The peri-operative management of patients under long-term anticoagulant 
therapy remains a great challenge for dentists. In recent years, studies have shown evidence to 
continue oral anticoagulant therapy for minor oral surgeries, emphasizing the role of local 
hemostasis. 
 
Type of Studies Reviewed: This systematic review included clinical trials that compared the 
use of topical tranexamic acid (TXA) versus other topical hemostatic agents, placebo or 
interruption/decrease of anticoagulant therapy for minor oral surgeries. The authors included 
only studies in which the investigators evaluated bleeding within the first postoperative week 
with need for clinical intervention. The risk of bias was assessed according to the Cochrane 
guidelines for clinical trials. The pooled relative risk (RR) was calculated for the effect of 
topical application of TXA on postsurgical bleeding. 
 
Results: 7 clinical trials were included in the meta-analysis. The combined RR for the number 
of patients receiving TXA in comparison to the control group was 0.42 (95% CI 0.21 to 0.84; 
p = 0.01), indicating a protective effect of topical TXA on bleeding after minor oral surgeries. 
Subgroup analysis revealed that topical TXA was effective to prevent postsurgical bleeding 
compared to placebo and epsilon-aminocaproic acid. No cases of thromboembolic events was 
reported in any study.  
 
Practical Implications: Irrigation of surgical site with TXA followed by mouthwash during 
the first postoperative week can reduce the risk of bleeding after minor oral surgeries in 
anticoagulated patients.   
Key words: Decision making; dental care for chronically ill patients; evidence-based 
dentistry; hemorrhage; oral surgical procedures. 
 
 
Introduction 
 Oral anticoagulants are widely used for primary prevention of thromboembolic events 
in patients with atrial fibrillation and prosthetic heart valves and secondary prevention after 
systemic embolism in patients with rheumaticmitral-valve disease, mitral-valve prolapse, 
mitral annular calcification, nonrheumaticmitral regurgitation, and mobile aortic atheromas or 
aortic plaques larger than 4 mm.1 However, the major drawback of oral anticoagulant therapy 
(OAT) is related to increased risk of bleeding after traumatic injuries and surgical 
procedures.2 Patients receiving OAT are generally older, present multiple comorbidities, and 
receive several medications.3 In addition, elderly patients usually  have high demand for oral 
surgery procedures, which can further increase their risk of bleeding and hinder the 
treatment.2,4 
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 Warfarin is the most used oral anticoagulant to control and prevent thromboembolic 
events classified as an antagonist of vitamin K, an essential cofactor for the synthesis of 
clotting factors II, VII, IX and X and protein C and S. Although warfarin has a narrow 
therapeutic range, the dose required to achieve therapeutic anticoagulation is very close that 
leads to over-anticoagulation. Therefore, patients receiving warfarin requires frequent 
monitoring to avoid potentially life-threating complication including the risk of serious 
bleeding.5 The median annual rate of major bleeding associated to the warfarin ranges from 
0.9 to 2.7 percent, especially in elderly patients, history of gastrointestinal bleeding, 
hypertension, cerebrovascular disease, serious heart disease, and renal insufficiency.6 
Regard to increased risk of bleeding, determining the clinical protocol at long-term 
OAT to reduce the risk during surgery or invasive procedures remains controversial; while 
different recommendations have been proposed including the reduction, discontinuation, or 
substitution of OAT with heparin prior to surgical procedure. However, there is strong 
evidence that OAT patients undergoing oral surgeries should not discontinue their medication 
due to the risk of thromboembolic complication.2 In the last years, studies have indicated that 
maintaining OAT associated to topical use of tranexamic acid (TXA) and other local 
hemostatic agents does not result in an increased risk of bleeding during and after minor oral 
surgeries.7–12 
TXA, a synthetic derivative of the amino acid lysine, is an antifibrinolytic agent that 
blocks lysine-bindings sites on plasminogen reducing the local degradation of fibrin by 
plasmin.  TXA works to stabilize and inhibit the degradation of existing clots, and is widely 
used to limit bleeding in clinical practice. A series of systematic reviews and meta-analyses 
were published showing strong evidence that TXA is effective in reducing blood loss and 
transfusion requirements in knee arthrosplasty13–15, hip13,15,16 and spinal surgeries17,18, without 
increased thromboembolic complications such as myocardial infarction, deep venous 
thrombosis, and pulmonary embolism. Similar results were observed in healthy patients 
during orthognathic surgery receiving intravenous TXA.19,20 However, to the best of our 
knowledge, there is no evidence about the efficacy and safety of topical TXA in reducing 
blood loss in anticoagulated patients undergoing minor oral surgery procedures. 
This systematic review meta-analyzed the outcomes of clinical trials investigating the 
efficacy and safety of topical TXA to prevent postoperative bleeding in anticoagulated 
patients undergoing minor oral surgery when compared to other hemostatic therapies. 
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Material and Methods 
This systematic review and meta-analysis was conducted following the PRISMA 
(Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement21 and 
supplemented by guidance from the Cochrane Collaboration Handbook.22 A protocol of this 
systematic review was designed a priori and was registered in the PROSPERO database 
(registration number CRD 42014013072). 
 
Search Strategy 
We searched for clinical trials at PubMed, SCOPUS, Cochrane Central Register of 
Controlled Trials (CENTRAL), OpenThesis and website clinicaltrials.gov (international 
database for clinical trials) from inception to May 2015. A grey-literature search was 
conducted through Google Scholar. Our search was restricted to studies published in full-text 
versions, without language restriction. The reference lists of all eligible studies and reviews 
were also manually scanned to identify additional studies for inclusion.  
The structured search strategy used the following terms: ((“tranexamic acid”) AND 
(“oral surgery” OR “oral surgical procedures” OR “dental extraction” OR “tooth extraction” 
OR “third molar”) AND (“oral hemorrhage” OR “hemorrhage” OR “blood loss”)). For the 
OpenThesis database, the search terms were (“tranexamic acid” AND “oral surgery”). No 
filter was performed to the search, to expand the number of eligible articles. 
 
Study Selection and Eligibility Criteria  
Two reviewers (PRSM-F and SJAV) independently screened the search results and 
identified studies that were potentially relevant based on paper’s title and abstract. Relevant 
studies were read in full-text and selected according to eligibility criteria. Disagreement 
between the two reviewers was resolved by consensus or by a third reviewer (TSS). 
 The following PICOT (population, intervention, controls, outcome, and study type) 
elements were used to define the eligibility criteria: (1) population: anticoagulated patients 
undergoing to the minor oral surgery; (2) intervention and controls: the use of topical TXA 
for at least 48h after surgery versus other topical hemostatic agent, placebo (innocuous 
solution) or interruption/decrease of anticoagulant therapy prior to the surgery; (3) predefined 
outcomes: bleeding within the first postoperative week with need for clinical intervention and 
20 
 
thromboembolic events (myocardial infarction, stroke, systemic embolism, thrombosis of a 
mechanical heart valve, thrombosis of the cardiac chamber, deep-vein thrombosis or 
pulmonary embolism); and (4) type: clinical trials. Eligible studies must report at least the 
number of patients or surgical sites with postoperative bleeding as end point. 
Data from patients with INR (International Normalized Ratio) or other blood 
coagulation parameters within the normal range in the preoperative period or with coagulation 
abnormalities including hemophilia and liver disease were excluded. In addition, we excluded 
studies or groups that modified the OAT and used perioperative intravenous or oral TXA on 
blood loss in minor oral surgery procedures. 
 
Data Extraction and Risk of Bias Assessment 
Using a standardized data extraction sheet, the following information was extracted 
and recorded from studies: demographic characteristics of study participants, pathology and 
anticoagulant medication, type of oral surgery, dosage and timing of TXA, control group 
intervention, duration of follow-up, and outcome data. 
The risk of bias was assessed according to the Cochrane guidelines for clinical trials. 
We assessed seven domains for evaluation: sequence generation and allocation concealment 
(selection bias), blinding of participants and personnel (performance bias), blinding of 
outcome assessment (detection bias), incomplete outcome data (attrition bias), selective 
outcome reporting (reporting bias), and other potential sources of bias. We rated the risk of 
bias as low, unclear, or high according to established criteria.22 
 
Data Synthesis 
 The pooled relative risk was calculated for the effect of topical application of TXA on 
postsurgical bleeding. A forest plot was used to graphically present the effect sizes and the 
95% CIs. Each study was represented by a square in the plot that was proportional to the 
study’s weight in the meta-analysis. A 2-tailed p < 0.05 was used to determine significance.   
Statistical heterogeneity was assessed using the Cochran Q test23 and quantified by the 
I2 index.24 A random-effects model of DerSimonian-Laird was used to pool estimates and 
corresponding 95% CI assuming that the risk for individual trials vary around pooled effect 
size.25 A possible source of between-study heterogeneity which we noted prior to performing 
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our study was the different strategies used in the control groups. Therefore, a subgroup 
analysis was performed according to this potential source of heterogeneity.   
To assess potential publication bias we created a funnel plot by plotting the individual 
estimates in log units against the standard error.26 “Leave-one-out” sensitivity analysis was 
conducted by omitting one study at a time and examining the influence of each individual 
study on the pooled effect size.27 All analyses were conducted using Review Manager 5.3 
(Cochrane IMS, Copenhagen, Denmark).  
 
Results 
 
Data Sources  
We identified 1630 potentially relevant studies from electronic databases, Google 
Scholar, and cross-references. After screening titles and abstracts, 21 full-text articles were 
assessed for eligibility and 7 clinical trials were included in the final analysis. Flow diagram 
of the selection of studies and specific reasons for exclusion are detailed in Figure 1.  
 
Study Characteristics 
The total number of patients included in the trials was 483. Dental extractions were the 
most common oral procedure, followed by periapical surgery and implants. Most patients 
aged over 60 years and received warfarin therapy before surgery. All studies used TXA for 
irrigation of surgical site and mouthwash (2 to 7 days) to prevent postoperative bleeding 
during the 7-day postoperative period. In three studies7,8,28, TXA was associated with other 
hemostatic agent.  
The efficacy of TXA was compared with placebo solution in two studies12,29, with 
EACA as a mouthwash in one study30, and with an absorbable hemostatic material in two 
studies.7,8 In the study by Sacco et al.28 and Borea et al.31, comparator was the reduction or 
discontinuation of OAT until INR values within therapeutic range (between 1.5 and 2.5). All 
patients received sutures after surgical procedures. The main characteristics (number of 
patients, age, anticoagulant therapy, intervention, procedures, and follow-up visits) of clinical 
trials are presented in Table 1. 
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Risk of Bias 
 Figure 2 provides a summary of risk of bias characteristics for all 7 clinical trials. For 
the domains of random sequence generation and allocation concealment, most studies (71.5%) 
had a high or unclear risk of bias, while 42.9% and 28.5% of studies had low risk of 
performance and detection bias, respectively. For all other domains (incomplete outcome 
data, selective reporting, and other bias), most of trials were rated as low risk of bias.  
 
Data Synthesis  
 The 7 clinical trials included in this analysis randomized 249 patients to receive TXA 
and 284 received other treatments assigned as controls. The combined RR for the number of 
patients receiving TXA in comparison to the control group was 0.42 (95% CI 0.21 to 0.84; p 
= 0.01), indicating a protective effect of topical TXA on bleeding after minor oral surgeries. A 
moderate between-study heterogeneity was observed (p = 0.22, I2 = 26%) (Figure 3). There 
were no cases of thromboembolic events in any study, in either the TXA or the control 
groups, during the one to 7 day follow-up period after surgery.  
 
Subgroup analysis and publication bias 
 Although all included clinical trials examined a similar question (effect of topical 
TXA for prevention of postsurgical bleeding in anticoagulated patients undergoing minor oral 
surgery procedures), we assumed the control group as a potential source of between-study 
heterogeneity once that is used on the relative risk calculation. We stratified the meta-analysis 
into four subgroups: TXA vs. placebo solution, TXA vs. EACA, association of TXA and 
absorbable hamostatic material vs. absorbable hamostatic material, and association of TXA 
and absorbable hamostatic material vs. reduced dosage of OAT. The heterogeneity decreased 
markedly from 26 to 0% within the subgroups, suggesting that the heterogeneity was 
attributable to the different strategies used to prevent postsurgical bleeding in the control 
group.  
 Subgroup analysis revealed that topical TXA was effective to prevent postsurgical 
bleeding compared to placebo (RR = 0.09; 95% CI 0.02 to 0.48; p = 0.004) and EACA (RR = 
0.12; 95% CI 0.01 to 0.94; p = 0.04). However, no significant difference was observed for the 
absorbable haemostatic material (RR = 0.77; 95% CI 0.32 to 1.86; p = 0.56) and reduced or 
23 
 
discontinued dosage of OAT (RR = 0.59; 95% CI 0.25 to 1.43; p = 0.24) (Figure 3). 
Sensitivity analysis indicated the robustness of our findings, and evidence of publication bias 
was not observed in our meta-analysis (Figure 4). 
 
Discussion 
 Although life expectancy has improved for decades due to gradual improvement in 
health-care delivery services, elderly people tends to have a higher prevalence of chronic 
diseases, physical disabilities, mental illnesses and other comorbidities.32 Since cardiovascular 
disease is the most common cause of mortality in elderly people worldwide, oral 
anticoagulants are widely used for long-term prevention or treatment of cardiovascular events, 
such as stroke and myocardial infarction. For this reason, the management of patients on OAT 
requiring surgical procedure remains a challenge due to the risk of increased bleeding if 
therapy is continued.33 
 TXA is one of the most common antifibrinolytic medication used in controlling blood 
loss after oral surgeries in anticoagulated patients. Recently, two meta-analyses19,20 of RCTs 
confirmed that intravenous TXA reduces intraoperative blood loss in orthognathic surgery, 
but high-level of evidence is lacking for the use of topical application. Our meta-analysis 
showed that irrigation of surgical site with TXA followed by mouthwash in anticoagulated 
patients without therapy modification or withdrawal might reduce the risk of bleeding during 
the first postoperative week, especially compared to placebo solution (91% decrease in risk) 
and EACA mouthwash (88% decrease in risk). 
 These findings are in contrast to those from the other studies which suggested that 
patients receiving OAT within the therapeutic range can be carried out safely and without 
complication to the minor oral surgical procedures without any additional hemostatic 
measures34–36, as the use of topical haemostatic agents. According to the Wahl37, however, 
although there are no well-documented cases of serious postoperative bleeding complications 
after dental surgery in patients receiving OAT within the therapeutic range, there are good 
legal reasons to continue OAT for dental surgery in addition to the application of local 
measures to control post-surgical bleeding. In a recent meta-analysis, it was observed that 
perioperative continuation of warfarin did not increase the risk of bleeding compared with 
discontinuing or modifying the warfarin dose for patients undergoing minor dental 
procedures.38 
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Although our subgroup analysis has shown no difference for the risk of bleeding 
between the use of topical TXA and anticoagulant dose modification, the risk of 
thromboembolic events should not be overlooked if OAT is modified before dental 
procedures.37 In a systematic review performed by Wahl37, in 542 documented cases in 493 
patients of withdrawing the OAT for dental procedures, 1% of patients had serious embolic 
complications, including 4 deaths. Therefore, our results also suggest that anticoagulant 
treatment does not need to be drawn or reduced before oral surgery, as long as local 
hemostatic measures including suture and irrigation of surgical site with TXA followed by 
mouthwash with this agent are performed for these patients.  
Other hemostatics agents such as autologous fibrin sealant, absorbable gelatin 
sponges, and oxidized cellulose polymer have also been indicated in surgical practice. 
Suwannuraks et al.39 reported the efficacy of a combination of celluloid splint and fibrin glue 
in controlling bleeding during oral surgeries. Others recommended the use of fibrin sealant in 
combination with absorbable gelatin sponge40 or oral swish and swallow rinses of TXA 
solution41for patients with bleeding disorders. Minimal bleeding complications were also 
observed using oxidized regenerated cellulose34 or gelatin sponge42after minor oral surgical 
procedures in anticoagulated patients. Interestingly, our results showed that local hemostasis 
with absorbable hemostatic materials (gelatin sponge, fibrin glue or oxidized regenerated 
cellulose) was not more effective in preventing bleeding than TXA mouthwash in 
combination with gelatin sponge or oxidized regenerated cellulose. Unfortunately, we didn´t 
find any study comparing the efficacy of topical application of TXA alone with absorbable 
hemostatic materials. Since TXA may be a better cost-effective option to minimize bleeding 
risks after minor oral surgeries, further studies are still necessary to support the superiority of 
TXA over absorbable hemostatic materials. 
Systemic infusion of antifibrinolytic agents has been used for many years to reduce 
bleeding and need for transfusion in various surgical procedures, including orthognathic 
surgeries.43 However, systemic administration of these agents can increase the tendency to 
thrombosis and the risk of thromboembolism. To avoid or at least reduce the risk of 
thromboembolic events such as deep vein thrombosis, myocardial infarction, and pulmonary 
embolism, topical TXA has been indicated for several surgical procedures.44–47 Our meta-
analysis suggests that topical TXA in minor oral surgeries is safe, since no cases of 
thromboembolic events was observed during the follow-up period up to 7-day after surgery in 
studies evaluated. Therefore, in addition to the efficacy in reducing the risk of bleeding in 
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anticoagulated patients, irrigation of surgical site with TXA followed by mouthwash can 
minimize its systemic absorption, and, consequently, concerns about possible side-effects.  
Although no evidence of publication bias, this systematic review presents some 
limitations. First, the quality of the evidence is limited to the quality of studies included in this 
meta-analysis. None of the studies had an overall low risk of bias. In most cases, we found 
potential bias for selection that may lead to large estimates of effects and problems to 
controlling for unknown and unmeasured factors.48 Second, the studies included in this meta-
analysis contain relatively small samples sizes, which may lead to an extreme beneficial 
treatment effect. The aim of the sample size calculations is to assure that statistical power is 
acceptable while maintaining a small probability of a type I error.49 In this meta-analysis, only 
one study29 reported the power calculation and estimates of sample size for planning the trial. 
Finally, we are unable to explore differences in TXA efficacy according to surgical type, 
duration of the surgery, mouthwash regimen, and preoperative and postoperative 
hematological data, which may lead in confounding and performance bias.  
 
Conclusions 
Despite these limitations, available data suggest that irrigation of surgical site with 
TXA followed by mouthwash during the first postoperative week can reduce the risk of 
bleeding after minor oral surgeries in anticoagulated patients with no risk of 
thromboembolism. However, additional trials should be conducted to compare TXA efficacy 
over absorbable hemostatic materials. 
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Legends 
 
Table 1. Characteristics of studies included in the meta-analysis. 
Figure 1. Flow chart of the search process. 
Figure 2. Risk of bias assessment.  
Figure 3. Forest plot for the risk of postosurgical bleeding.   
Figure 4. Funnel plot assessing potential publication bias.  
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Figure 1. Flow chart of the search process. 
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Figure 2. Risk of bias assessment. 
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Figure 3. Forest plot for the risk of postosurgical bleeding. 
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Figure 4. Funnel plot assessing potential publication bias. 
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5) CONSIDERAÇÕES FINAIS 
 
 Os dados avaliados nesta meta-análise sugerem a eficácia do uso do ácido tranexâmico 
tópico no controle do sangramento de cirurgias orais menores em pacientes sob terapia 
anticoagulante na primeira semana de pós-operatório, em especial em relação ao grupo 
placebo, além de segurança em relação ao risco de eventos tromboembólicos. Entretanto, a 
análise mostra que mais estudos clínicos bem delineados são necessários para avaliar a 
efetividade do ácido tranexâmico tópico principalmente em comparação a outros agentes 
hemostáticos locais. 
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6) COMUNICADO A IMPRENSA (PRESS RELEASE) 
 
A EFICÁCIA DO ÁCIDO TRANEXÂMICO EM CIRURGIAS ODONTOLÓGICAS  
Com o crescente acesso e informação na área odontológica, os pacientes estão cada 
vez mais mantendo sua dentição natural à medida que envelhecem. Neste contexto, as 
cirurgias orais passaram a ser mais indicadas em pessoas idosas, que apresentam alguma 
doença geral, dentre elas as alterações cardíacas ou vasculares. Desta maneira muitos 
pacientes que necessitam de procedimento cirúrgico odontológico fazem uso de 
anticoagulantes orais, que são drogas comumente prescritas para prevenção e tratamento de 
eventos tromboembólicos associados a condições clínicas importantes como fibrilação atrial, 
doença cardíaca isquêmica, acidente vascular cerebral entre outras.  
Porém, estes pacientes, quando necessitam de uma cirurgia na boca ou outro 
procedimento cirúrgico, tem o risco aumentado de sangramento, visto que esta é a maior 
desvantagem dos anticoagulantes orais. Baseado nisso, foi realizada uma análise, através de 
uma revisão sistemática, de vários artigos que descreveram o uso do ácido tranexâmico em 
forma de bochecho no controle do sangramento após cirurgias bucais em pacientes em uso de 
anticogulantes orais. Os dados da pesquisa revelaram a eficácia deste agente hemostático no 
controle do sangramento durante a primeira semana de pós-operatório, sendo mais 
significante quando comparado ao placebo. Entretanto, foi verificada a necessidade de estudos 
adicionais que comparem a eficácia do ácido tranexâmico em relação a outros agentes 
hemostáticos locais, como as esponjas de fibrina.   
 
Contatos: Sara Vasconcellos (sarajulianad@yahoo.com.br) e Paulo Saquete (martins-
filho@ufs.br). Universidade Federal de Sergipe, Hospital Universitário, Laboratório de 
Patologia Investigativa. Rua Cláudio Batista, s/n. Bairro Sanatório. Aracaju, Sergipe, Brasil. 
CEP: 49060-100. 
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Full title of the organisational affiliations for this review, and website address if available. This field may be completed
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as 'None' if the review is not affiliated to any organisation.
None
Website address:
11 Review team members and their organisational affiliations
Give the title, first name and last name of all members of the team working directly on the review. Give the
organisational affiliations of each member of the review team.
   Title First name Last name Affiliation
Professor Paulo Martins-Filho Universidade Federal de Sergipe
Dr Thiago Santos Universidade Federal de Sergipe
Professor André Luis Faria-e-Silva Universidade Federal de Sergipe
Ms Sara Juliana Vasconcellos Universidade Federal de Sergipe
Professor Maria de Fátima Melo Universidade Federal de Sergipe
12 Funding sources/sponsors
Give details of the individuals, organizations, groups or other legal entities who take responsibility for initiating,
managing, sponsoring and/or financing the review. Any unique identification numbers assigned to the review by the
individuals or bodies listed should be included.
There was no funding source for this study
13 Conflicts of interest
List any conditions that could lead to actual or perceived undue influence on judgements concerning the main topic
investigated in the review.
Are there any actual or potential conflicts of interest?
None known
14 Collaborators
Give the name, affiliation and role of any individuals or organisations who are working on the review but who are not
listed as review team members.
   Title First name Last name Organisation details
Review methods
15 Review question(s)
State the question(s) to be addressed / review objectives. Please complete a separate box for each question.
Is topical application of tranexamic acid more effective than placebo in preventing post-operative bleeding in
anticoagulated patients undergoing minor oral surgery procedures?
16 Searches
Give details of the sources to be searched, and any restrictions (e.g. language or publication period). The full search
strategy is not required, but may be supplied as a link or attachment.
We will search MEDLINE, SCOPUS, Google Scholar, Cochrane Central Register of Controlled Trials (CENTRAL) and
international database for clinical trials www.clinicaltrials.gov from inception to May 2015. Our search will include
RCTs published in full-text versions, without language restriction. The search will include a hand search of cross-
references from original articles and reviews. Search terms will include “tranexamic acid”, “oral surgery”, “oral surgical
procedures”, “dental extraction”, “tooth extraction”, “third molar”, “anticoagulants”, “oral hemorrhage”, “hemorrhage”,
and “oral hemorrhage”, “blood loss”. 
17 URL to search strategy
If you have one, give the link to your search strategy here. Alternatively you can e-mail this to PROSPERO and we
will store and link to it.
I give permission for this file to be made publicly available
Yes
18 Condition or domain being studied
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Give a short description of the disease, condition or healthcare domain being studied. This could include health and
wellbeing outcomes.
Post-operative bleeding in anticoagulated patients undergoing minor oral surgery procedures
19 Participants/population
Give summary criteria for the participants or populations being studied by the review. The preferred format includes
details of both inclusion and exclusion criteria.
Anticoagulated patients who underwent minor oral surgery
20 Intervention(s), exposure(s)
Give full and clear descriptions of the nature of the interventions or the exposures to be reviewed
Local acid tranexamic
21 Comparator(s)/control
Where relevant, give details of the alternatives against which the main subject/topic of the review will be compared
(e.g. another intervention or a non-exposed control group).
Other local hemostatic agent or placebo (innocuous solution, interruption or decrease of anticoagulant therapy prior to
the surgery)
22 Types of study to be included initially
Give details of the study designs to be included in the review. If there are no restrictions on the types of study design
eligible for inclusion, this should be stated.
Randomized controlled trials
23
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GUIDE FOR AUTHORS
.
INTRODUCTION
Manuscript submission
New manuscripts. All new manuscripts must be submitted via JADA’s online submission and review
website, JADA ScholarOne Manuscripts. (Authors who do not yet have an account on the website
should click the “Create Account” link on the upper right-hand corner of the JADA ScholarOne
Manuscripts welcome page and follow the step-by-step process to open an account.) On the dashboard
page, authors should select the Corresponding Author Center. In the Corresponding Author Center,
they should click the “Click here to submit a new manuscript” link.
Author identification and roles. The author should include a letter providing each author’s name,
degrees, professional title, work affiliations, complete address, telephone and fax numbers, and email
address. That cover letter can be typed in on the JADA ScholarOne Manuscripts site in the field
provided, or it can be uploaded to the site as a word-processed document. In addition, each author
must provide a statement of responsibility detailing what he or she contributed to the manuscript.
That statement can be uploaded as a separate document (it is recommended that statements from
all authors be placed in a single document).
Originality and exclusivity. The JADA Editor will consider only articles that are original, have not been
published elsewhere and have been submitted exclusively to JADA.
BEFORE YOU BEGIN
Clinical trials
CONSORT statement. Authors of articles about clinical trials must
adhere to the Consolidated Standards of Reporting Trials statement
(http://www.consort-statement.org/consort-statement/overview0). Authors of manuscripts about
clinical trials must use intention-to-treat analysis.
Registration of clinical trials. Effective March 1, 2013, as a condition for publication of any report of
a clinical trial that began enrollment of participants on or after March 1, 2013, JADA requires that
the clinical trial be registered publicly before any participants are enrolled in the study. Trials that
began enrollment prior to March 1, 2013 also must be registered, but registration of such trials after
enrollment of participants has begun is acceptable. The specific trial registry name and the registry
number (for example, "ClinicalTrials.gov identifier NCT00000000" must be submitted with each
manuscript that is a report of a clinical trial. Observational studies—those in which the investigator
does not assign the intervention—will not require registration. JADA editors will check manuscripts on
submission to determine if the study required registration. Clinical trials need not be registered on any
specific website; a list of registries acceptable to JADA is available on the International Committee of
Medical Journal Editors website (http://www.icmje.org/about-icmje/faqs/clinical-trials-registration).
If such a manuscript is accepted for publication, the trial registry name and registration number will
be published at the end of the article's abstract.
Systematic reviews and meta-analyses
PRISMA statement. Authors of systematic reviews must adhere to Preferred
Reporting Items for Systematic Reviews and Meta-Analyses, available at
http://www.prisma-statement.org/statement.htm.
Manuscript designation
When published, manuscripts will be placed in one of the JADA departments listed below. The editor
will designate each submission to the appropriate section.
Unless otherwise noted, manuscripts must be no longer than 10 double-spaced pages (roughly
3,000 words), exclusive of title page, abstract, acknowledgments, references and illustrations (tables,
figures, text boxes).
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Peer-reviewed articles
Original Contributions. Articles with a clinical and practical focus, covering topics such as esthetic
and restorative care, oral-systemic health, pharmacology, specialty dental practice, and informatics
and technology; articles describing the results of clinical, laboratory and population-based research
pertinent to dentistry and providing foundation knowledge for future application; articles regarding
epidemiologic and policy issues.
Non-peer-reviewed material
Letters to the Editor. Brief comments on issues raised and articles published in JADA. A letter about
a particular article will be forwarded to the article’s author for comment, if the letter is selected for
publication. The JADA Editor reserves the right to edit the letters into a publishable format (550
words, maximum of five references, no illustrations). A letter concerning a recent JADA article will
have the best chance of acceptance if it is received within two months of the article’s publication.
Letter writers are asked to disclose any personal or professional affiliations or conflicts of interest that
readers may wish to take into consideration in assessing their stated opinions. Brevity is appreciated.
By sending a letter to the editor, the author acknowledges and agrees that the letter and all rights
of the author in the letter become the property of The Journal. Letters may be submitted via email
to jadaletters@ada.org; by fax to 312.440.3538; or by mail to 211 E. Chicago Ave., Chicago, Ill.
60611-2678.
Role of the funding source
You are requested to identify who provided financial support for the conduct of the research and/or
preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in
the collection, analysis and interpretation of data; in the writing of the report; and in the decision to
submit the article for publication. If the funding source(s) had no such involvement, then this should
be stated.
Funding body agreements and policies
Elsevier has established agreements and developed policies to allow authors whose articles appear in
journals published by Elsevier, to comply with potential manuscript archiving requirements as specified
as conditions of their grant awards. To learn more about existing agreements and policies, please
visit http://www.elsevier.com/fundingbodies.
National Institutes of Health public access policy: authors’ responsibilities
The National Institutes of Health (NIH) Public Access Policy implements a law passed in December
2007 that affects authors who receive funding from the NIH. Effective April 7, 2008, the law mandates
that all peer-reviewed articles that arise, in whole or in part, from direct costs funded by NIH, or
from NIH staff, that are accepted for publication by a peer-reviewed journal—including JADA—must
be deposited with the National Library of Medicine’s PubMed Central, in the form of a copy of the
manuscript’s final version on its acceptance. NIH provides a Website at http://publicaccess.nih.gov
that contains answers to questions authors may have about this policy.
When the author deposits the accepted manuscript with PubMed Central, he or she should specify
that the manuscript is not to be made available until 12 months after publication (not acceptance).
Thereby, the manuscripts will be made publicly available by PubMed Central at the same time that
JADA makes its full text available to the public free of charge.
JADA holds the copyright to all material it publishes except for material authored solely by U.S.
government employees.
Authors with NIH funding should note that access to their articles will be open to all readers, in
accordance with the law.
Checklist
Please indicate in your submission whether any of the following statements applies to you or any co-
author of your article. If so, Elsevier will deposit your manuscript, if accepted, with PubMed Central
on your behalf. directly funded by an NIH grant or cooperative agreement active in Fiscal Year 2008
(October 1, 2007-September 30, 2008) or beyonddirectly funded by a contract signed on or after
April 7, 2008directly funded by the NIH Intramural Programpaid a salary by NIH
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Funding body agreements and policies
Elsevier has established a number of agreements with funding bodies which allow authors
to comply with their funder's open access policies. Some authors may also be reimbursed
for associated publication fees. To learn more about existing agreements please visit
http://www.elsevier.com/fundingbodies.
After acceptance, open access papers will be published under a noncommercial license. For authors
requiring a commercial CC BY license, you can apply after your manuscript is accepted for publication.
Open access
This journal offers authors a choice in publishing their research:
Open access
• Articles are freely available to both subscribers and the wider public with permitted reuse
• An open access publication fee is payable by authors or on their behalf e.g. by their research funder
or institution
Subscription
• Articles are made available to subscribers as well as developing countries and patient groups through
our universal access programs (http://www.elsevier.com/access).
• No open access publication fee payable by authors.
Regardless of how you choose to publish your article, the journal will apply the same peer review
criteria and acceptance standards.
For open access articles, permitted third party (re)use is defined by the following Creative Commons
user licenses:
Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)
For non-commercial purposes, lets others distribute and copy the article, and to include in a collective
work (such as an anthology), as long as they credit the author(s) and provided they do not alter or
modify the article.
The open access publication fee for this journal is USD 2500, excluding taxes. Learn more about
Elsevier's pricing policy: http://www.elsevier.com/openaccesspricing.
Green open access
Authors can share their research in a variety of different ways and Elsevier has a number of green
open access options available. We recommend authors see our green open access page for further
information (http://elsevier.com/greenopenaccess). Authors can also self-archive their manuscripts
immediately and enable public access from their institution's repository after an embargo period. This
is the version that has been accepted for publication and which typically includes author-incorporated
changes suggested during submission, peer review and in editor-author communications. Embargo
period: For subscription articles, an appropriate amount of time is needed for journals to deliver value
to subscribing customers before an article becomes freely available to the public. This is the embargo
period and begins from the publication date of the issue your article appears in.
This journal has an embargo period of 12 months.
PREPARATION
Manuscript format
Technical specifications. Manuscripts submitted to JADA must be prepared in Microsoft Word. No
manuscripts prepared in WordPerfect or other word processing software can be reviewed. Also, no
illustrations or other material prepared in PowerPoint will be accepted for review. If your material
was prepared in PowerPoint, please copy it into a Microsoft Word document or submit it as a PDF,
a JPEG, a TIFF or an EPS file.
Length. Unless otherwise noted above, manuscripts must be no longer than 10 double-spaced
pages (roughly 3,000 words), exclusive of title page, abstract, acknowledgments, references and
illustrations.
NOTE: The Journal does not accept submissions of serial articles (Part I, Part II, etc.).
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Page setup. Pages should have 1-inch margins and must be numbered consecutively throughout the
document.
Title page. Each manuscript should have a title page bearing the complete title of the manuscript
and complete information on all authors. It should be the first page of the manuscript. Each author’s
degrees must be listed on the title page. JADA generally does not publish U.S. fellowships and honorary
degrees and designations. Degrees below the master’s level generally are not listed, unless they are
the highest degree attained.The title page should designate the corresponding author and list that
author’s complete mailing address for the purposes of directing reprint requests after publication.
Authors. The people listed as authors should be those who made an intellectual contribution to
the manuscript. All authors should be listed with their affiliations, their academic degrees and their
scientific or clinical contributions to the paper. Again, the editor and publisher reserve the right to ask
for justification for each author’s inclusion.
Practical implications. Authors must ensure that their articles describe practical implications of their
findings. In other words, they must answer the question, “What does this mean for a dentist’s
practice?”
List of resources. When possible, authors should provide information on further resources regarding
the clinical and practical implications of their articles.
Acknowledgments. Acknowledgments should be submitted on a separate page.
Illustrations. A maximum of four figures—charts, graphs or photographs—and four tables may
be submitted. (See next paragraph for an exception to this rule.) Each separate chart, graph or
photograph will be counted as a separate illustration; illustrations should not be grouped together as a
single illustration. Tables and figures should augment, not repeat, the text. Figures and tables should
be numbered consecutively according to the order in which they are cited in the text. Regarding clinical
figures, JADA will accept only digital files of at least 4 inches (roughly 100 millimeters) in width and
at least 300 or more dots per inch and in JPEG, TIFF or EPS format. These may be uploaded on JADA
ScholarOne Manuscripts. JADA cannot accept original histologic slides and radiographs. However, The
Journal will accept digital files of radiographs, magnetic resonance images and magnetic resonance
angiograms. The publisher reserves the right to reject any figure that does not meet the necessary
quality standards for publication. (Exception. For only articles on esthetic care, authors are invited
to provide sufficient numbers of high-quality photographs to present their material comprehensively,
provided that there is an appropriate ratio of text to photographs: the length of the manuscript must
be sufficient to support placement of photographs within the text. As a rule of thumb, assume an
outside limit of three photographs per manuscript page.) Any patient who is clearly identified in the
article (either in text or in photographs) must sign a form indicating his or her consent to be thus
depicted in the article. This consent form (PDF) must be submitted with the manuscript.
General points
• Make sure you use uniform lettering and sizing of your original artwork.
• Preferred fonts: Arial (or Helvetica), Times New Roman (or Times), Symbol, Courier.
• Number the illustrations according to their sequence in the text.
• Use a logical naming convention for your artwork files.
• Indicate per figure if it is a single, 1.5 or 2-column fitting image.
• Please note that individual figure files larger than 10 MB must be provided in separate source files.
A detailed guide on electronic artwork is available on our website:
http://www.elsevier.com/artworkinstructions.
You are urged to visit this site; some excerpts from the detailed information are given here.
Formats
Regardless of the application used, when your electronic artwork is finalized, please 'save as' or
convert the images to one of the following formats (note the resolution requirements for line drawings,
halftones, and line/halftone combinations given below):
EPS (or PDF): Vector drawings. Embed the font or save the text as 'graphics.'
TIFF (or JPG): Color or grayscale photographs (halftones): always use a minimum of 300 dpi.
TIFF (or JPG): Bitmapped line drawings: use a minimum of 1000 dpi.
TIFF (or JPG): Combinations bitmapped line/half-tone (color or grayscale): a minimum of 500 dpi
is required.
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Please do not:
• Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); the resolution is too low.
• Supply files that are too low in resolution.
• Submit graphics that are disproportionately large for the content.
Illustration services. Elsevier's WebShop (http://webshop.elsevier.com/illustrationservices) offers
Illustration Services to authors preparing to submit a manuscript but concerned about the quality of
the images accompanying their article. Elsevier's expert illustrators can produce scientific, technical
and medical-style images, as well as a full range of charts, tables and graphs. Image 'polishing' is also
available, where our illustrators take your image(s) and improve them to a professional standard.
Please visit the website to find out more.
Supplementary data. This material should be submitted at each submission of the manuscript (in
other words, with the original and any revisions) to permit full review.
JADA structured abstracts
Features in the Original Contributions section in JADA include structured abstracts, the formats for
which are described below. The headings indicated here should be included in the abstract. Authors
should develop the abstract according to the type of manuscript they are submitting, with the
understanding that the editors could designate the manuscript as a different type and require a
revision in the abstract.
No abstract may exceed 250 words. If an abstract goes over that word count, JADA ScholarOne
Manuscripts will flag it and direct the author to shorten the abstract. The word counts given in
parentheses after each subhead are not requirements, merely suggestions to help keep authors within
the 250-word limit. As long as an abstract in total does not exceed 250 words regardless of the length
of the individual sections, it will be acceptable.
Original Contributions: full article
Background (30 words). A summary of the general topic and the purpose or hypotheses of the study.
Methods (50 words). A description of the materials (generic names of drugs and equipment should
be used, unless the particular brands are crucial to the study); the methods (including the type of
study design); the participants (important eligibility criteria, number and selection process).
Results (50 words). A statement of the primary results of the study; the types of analyses used should
be indicated, as should levels of statistical significance and confidence intervals.
Conclusions (30 words). A statement of the conclusions (the answers to the hypotheses posed at the
beginning of the study). Only the conclusions that are directly supported by the evidence provided
by the study should be included. Any need for further study should be indicated.
Practical Implications (30 words). A description of the practical implications of the findings; in
other words, an answer to the question, "What does this mean for a dentist's practice?" Where
possible, authors should provide information on further resources regarding the clinical and practical
implications of their articles.
Key Words (3-10 words). A list of key words highlighting the article's most important topics. Note:
JADA ScholarOne Manuscripts offers an extensive list of key words from which authors may choose.
Original Contributions: systematic review
Background (30 words). A summary of the objective of the literature review, whether it is cause
(etiology), diagnosis, prognosis, therapy or prevention.
Types of Studies Reviewed (50 words). A description of the types of studies reviewed, including
identification of the criteria used to select them and the method by which these criteria were applied.
Results (75 words). A statement of the main results of the review that outlines the methods used to
obtain these results and identifies the sources of variation between studies.
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Practical Implications (30 words). A description of the practical implications of the findings; in
other words, an answer to the question, "What does this mean for a dentist's practice?" Where
possible, authors should provide information on further resources regarding the clinical and practical
implications of their articles.
Key Words (3-10 words). A list of key words highlighting the article's most important topics. Note:
JADA ScholarOne Manuscripts offers an extensive list of key words from which authors may choose.
Original Contributions: case report
Background (30 words). A summary of the general topic, the disorder being discussed and the purpose
of the article.
Case Description (75 words). A description of the disorder as manifested in the cases presented in
the article, as well as the treatment undertaken and the expected vs. actual outcomes.
Practical Implications (30 words). A description of the practical implications of the findings; in
other words, an answer to the question, "What does this mean for a dentist's practice?" Where
possible, authors should provide information on further resources regarding the clinical and practical
implications of their articles.
Key Words (3-10 words). A list of key words highlighting the article's most important topics. Note:
JADA ScholarOne Manuscripts offers an extensive list of key words from which authors may choose.
Manuscript style
Basic style/writing requirements. The foundation of JADA style is the most recent edition of the
American Medical Association Manual of Style. The purpose of any piece of writing is to deliver
information. This requires the author to define his or her message and to present it in a way that is
readily understood by and engaging to the reader. Manuscripts should be written in active voice and
declarative sentences for a clear, concise style. The overall tone of these reports should be factual
and professional, and thus suitable for a scholarly journal. Authors are allowed to express a personal
opinion as long as the basis for that opinion is stated plainly. For example, an author may express
an opinion “based on long experience and intensive observation.” Other statements of opinion and
all statements of fact require references from the appropriate published literature (dental, medical,
epidemiologic, practice management, etc.).
Manuscript title. Authors are invited to write titles for their articles. Titles should be as brief as possible
while clearly conveying the main point or purpose of the article. Short subheads also should be used
throughout the article to highlight key points. All submissions, including titles and subheads, are
subject to change during the editing process.
Statistical material. Authors are required to include confidence intervals (CIs) with all P values.
References. All published references should be cited in the text and numbered consecutively. No
references should be cited in the abstract. Each reference should be cited only once; on subsequent
citations, the original number should be used. Personal communications and unpublished data should
not be numbered, but should be cited in the text as follows:
(G Edmunds, DDS, oral communication, November 2004)
Authors citing sources from the World Wide Web should make use of WebCite. WebCite is an entirely
free service for authors who want to refer to Web material, regardless of the publication for which
they are writing. It is an archiving system for Web references (cited Webpages and Websites) that
can be used by authors, editors and publishers of scholarly papers and books to ensure that cited
Web material will remain available to readers in the future. If Web references cited in JADA articles
are not archived, future readers may encounter a "File Not Found" error when clicking on a cited URL.
A Web citation archived on http://www.webcitation.org will not disappear in the future.
Citations in the reference list should follow this basic style: Periodical
1. Lauterbach M, Martins IP, Castro-Caldas A, et al. Neurological outcomes in children with and without
amalgam-related mercury exposure: seven years of longitudinal observations in a randomized trial.
JADA 2008;139(2):138-145. Book
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2. Cohen S, Burns RC. Pathways of the pulp. 8th ed. St. Louis: Mosby; 2002:196. Book chapter
3. Byrne BE, Tibbetts LS. Conscious sedation and agents for the control of anxiety. In: Ciancio SG,
ed. ADA Guide to Dental Therapeutics. 3rd ed. Chicago: American Dental Association; 2003:17-53.<li
Government publication
4. Medicine for the public: Women’s health research. Bethesda, Md.: U.S. Department of Health
and Human Services, Public Health Service, National Institutes of Health; 2001. DHHS publication
02-4971. World Wide Website
5. Hoffman ED, Klees BS, Curtis CA. Brief summaries of Medicare & Medicaid: Title
XVIII and Title XIX of the Social Security Act as of November 1, 2007. Baltimore, Md.:
U.S. Department of Health and Human Services, Center for Medicare & Medicaid Services,
Office of the Actuary; 2007. “http://www.cms.hhs.gov/ MedicareProgramRatesStats/downloads/
MedicareMedicaidSummaries2007.pdf” Accessed Aug. 28, 2008. Publication in press
6. McCoy J. Alteration in periodontal status as an indicator of general health. JADA (in press). NOTE:
Authors should double-check the status of any in-press work cited in their reference lists before
submitting the final manuscript to JADA. Presentation
7. Eichenstadt L, Brenner T. Caries levels among low-income children: report of a three-year study.
Paper presented at: 146th Annual Session of the American Dental Association; Oct. 7, 2005;
Philadelphia.
Review
Peer review. Articles in JADA are subject to a single-masked peer review process: reviewers know
the identity of a manuscript’s author(s), but authors do not know the identity of the reviewers.
(Authors do have an opportunity to suggest reviewers on JADA ScholarOne Manuscripts; they also
have an opportunity to request the exclusion of particular reviewers from critiquing their manuscript.
NOTE: Authors may not include as a preferred reviewer anyone who works at their own institutions.)
Reviewers keep their critiques strictly confidential. Because the reviewers volunteer their time,
reviews may take from three to four weeks to complete.
Decision. Once the reviewers have completed their critiques, the editor examines their comments
and makes a decision about the manuscript’s disposition: accept, minor revisions, major revisions,
or reject.
Editing. JADA reserves the right to edit manuscripts to ensure conciseness, clarity and stylistic
consistency and to fit articles to available space. After accepted articles are edited, they are returned
to the authors for review and comment before publication. Authors will have the opportunity to review
a PDF proof of their articles after they are typeset.
Authors' responsibilities
Ethical approval of studies and informed consent/assent. For all manuscripts reporting data from
studies involving human participants, human specimens or animals, JADA requires that the study
have received formal review and approval, or formal review and waiver, by an appropriate institutional
review board or ethics committee. This review and approval or waiver should be described in the
manuscript’s Methods section. Authors may be asked to request that the institutional review board
provide directly to the editor documentation of the formal review and recommendation from the
body responsible for ethical oversight of the study. For investigations involving humans or human
specimens, authors should state in the Methods section that they obtained informed consent/assent
from the study participants.
Personal communications and unpublished data. JADA requires that authors request and receive
permission from each person identified in the manuscript as a source of information in a personal
communication or as a source for unpublished data. By submitting their manuscripts, authors
represent and warrant to JADA that such permission has been obtained, if applicable. JADA strongly
recommends that such permissions be in writing and that authors should maintain the signed
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statements in their records for a reasonable period of time after publication of their work in JADA.
Authors must specify in the manuscript the date of the communication or the data, as well as whether
the communication was written or oral.
Copyright transfer. The American Dental Association owns the copyright for all editorial content
published in The Journal. Each author on a manuscript must submit a statement transferring copyright
to the ADA. After a manuscript is submitted and the editorial staff has checked it in, each author
will receive an email prompting him or her to log into JADA ScholarOne Manuscripts, visit the
Corresponding Author Center, complete the copyright transfer form (as well as the conflict of interest
form, which is discussed in the Disclosure section below) and submit it as directed in ScholarOne.
Manuscripts submitted without the requisite signed Copyright Transfer Agreements will not be
reviewed unless and until JADA’s Editor receives a valid, executed JADA Copyright Transfer Agreement
from each author. If the manuscript is rejected by the ADA, all copyrights in the manuscript will be
retained by the author(s). All accepted manuscripts and their accompanying illustrations become the
permanent property of the American Dental Association and may not be published elsewhere in full
or in part, in print or electronically, without written permission from the ADA’s Publishing Division.
Reprint permission. If the manuscript contains any material, either text or illustrations, that is either
exactly reproduced or adapted from a published source, the author is responsible for obtaining written
permission from the publisher of that source work—or the person or agency holding the copyright, if
not the publisher—to reproduce the material in JADA. JADA will not reproduce such material without
written permission. The official JADA template letter for this purpose is available online in Microsoft
Word format. The author must submit a copy of the permission letter and provide JADA with complete
citation information for the reproduced material.
Consent forms. Any person who is clearly identified in the article (either in text or in photographs)
must sign a form indicating his or her consent to be thus depicted in the article. This consent form
(PDF) must be submitted with the manuscript.
Response to letters to the editor. An author whose article is published in JADA is expected to prepare
a response to any letter to the editor about his or her article that the editor deems appropriate for
publication. (For further information, see the Letters to the Editor section above under Manuscript
Designation, Non-Peer-Reviewed Material.)
Disclosure
Each author must disclose any financial, economic or professional interests that may influence
positions presented in the article. This disclosure will be published with the article. After a manuscript
is submitted and the editorial staff has checked it in, each author will receive an email prompting
him or her to log into JADA ScholarOne Manuscripts, visit the Corresponding Author Center, complete
the conflict of interest form (as well as the copyright transfer form, which is discussed in the Review
section above) and submit it as directed in ScholarOne. Manuscripts submitted without the requisite
signed conflict of interest forms will not be reviewed unless and until JADA’s Editor receives a valid,
executed JADA conflict of interest form from each author.
Reference management software
Most Elsevier journals have their reference template available in many of the
most popular reference management software products. These include all products
that support Citation Style Language styles (http://citationstyles.org), such as Mendeley
(http://www.mendeley.com/features/reference-manager) and Zotero (https://www.zotero.org/), as
well as EndNote (http://endnote.com/downloads/styles). Using the word processor plug-ins from
these products, authors only need to select the appropriate journal template when preparing their
article, after which citations and bibliographies will be automatically formatted in the journal's style.
If no template is yet available for this journal, please follow the format of the sample references and
citations as shown in this Guide.
Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following
link:
http://open.mendeley.com/use-citation-style/the-journal-of-the-american-dental-association
When preparing your manuscript, you will then be able to select this style using the Mendeley plug-
ins for Microsoft Word or LibreOffice.
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Submission checklist
Before submitting a manuscript, the author should make sure he or she has completed all the
necessary steps. Electronic files of the manuscript and each table and figure should be uploaded.
A copyright transfer statement and a conflict of interest form, signed by each author, should be
either scanned and uploaded to JADA ScholarOne Manuscripts or faxed to the JADA editorial office at
1-716.829.6053. Please do not submit your forms until you submit your manuscript. The manuscript
should include a structured abstract in the proper format (according to the JADA department to which
it is being submitted). All references should be checked for accuracy, correct format and completeness.
If applicable, acknowledgments should be included in the manuscript on a separate page. Complete
information—name, degrees, position or title, address, phone and fax numbers, email address—
should be included for the corresponding author.
AFTER ACCEPTANCE
Use of the Digital Object Identifier
The Digital Object Identifier (DOI) may be used to cite and link to electronic documents. The DOI
consists of a unique alpha-numeric character string which is assigned to a document by the publisher
upon the initial electronic publication. The assigned DOI never changes. Therefore, it is an ideal
medium for citing a document, particularly 'Articles in press' because they have not yet received their
full bibliographic information. Example of a correctly given DOI (in URL format; here an article in the
journal Physics Letters B):
http://dx.doi.org/10.1016/j.physletb.2010.09.059
When you use a DOI to create links to documents on the web, the DOIs are guaranteed never to
change.
Proofs
One set of page proofs (as PDF files) will be sent by e-mail to the corresponding author (if we do
not have an e-mail address then paper proofs will be sent by post) or, a link will be provided in
the e-mail so that authors can download the files themselves. Elsevier now provides authors with
PDF proofs which can be annotated; for this you will need to download Adobe Reader version 9 (or
higher) available free from http://get.adobe.com/reader. Instructions on how to annotate PDF files
will accompany the proofs (also given online). The exact system requirements are given at the Adobe
site: http://www.adobe.com/products/reader/tech-specs.html.
If you do not wish to use the PDF annotations function, you may list the corrections (including
replies to the Query Form) and return them to Elsevier in an e-mail. Please list your corrections
quoting line number. If, for any reason, this is not possible, then mark the corrections and any other
comments (including replies to the Query Form) on a printout of your proof and return by fax, or scan
the pages and e-mail, or by post. Please use this proof only for checking the typesetting, editing,
completeness and correctness of the text, tables and figures. Significant changes to the article as
accepted for publication will only be considered at this stage with permission from the Editor. We
will do everything possible to get your article published quickly and accurately. It is important to
ensure that all corrections are sent back to us in one communication: please check carefully before
replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely
your responsibility.
Online ahead of print
To make your research available as quickly as possible, JADA now publishes articles online ahead of
print shortly after the author approves the page proofs. These can be found under the "Online ahead
of print" section of the JADA website (http://jada.ada.org). The articles published online ahead of
print will be clearly marked as Corrected Proofs. Corrected Proofs are versions of articles that have
been peer reviewed, accepted, and copyedited and include the author's corrections. No major changes
are expected to be made to these articles before final publication.
The articles published online ahead of print can be cited as follows: Author(s). Article title (date article
published online ahead of print). JADA. Digital object identifier (DOI). Once the article is assigned to
a volume and issue of JADA, the Corrected Proof version will be removed and the Final version will
appear online, accompanied by the year of publication and the volume, issue, and page numbers.
The date an article was first made available online will be carried over.
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Author’s preprints and complimentary copies
The corresponding author, at no cost, will receive two copies of the JADA issue containing the article,
and a PDF file of the article via e-mail (the PDF file is a watermarked version of the published article and
includes a cover sheet with the journal cover image and a disclaimer outlining the terms and conditions
of use). For an extra charge, paper offprints can be ordered via the offprint order form which is sent
once the article is accepted for publication. Both corresponding and co-authors may order offprints
at any time via Elsevier's WebShop (http://webshop.elsevier.com/myarticleservices/offprints).
Authors requiring printed copies of multiple articles may use Elsevier WebShop's
'Create Your Own Book' service to collate multiple articles within a single cover
(http://webshop.elsevier.com/myarticleservices/offprints/myarticlesservices/booklets).
Open access policy
Full-text JADA articles from 1995 to the present may be found on the ADA’s Website at
http://jada.ada.org.
1. ADA members and paid JADA subscribers have full access free of charge to all issues and all content
in the JADA Online archive.
2. The following content is free to all visitors at all times: Table of Contents and Abstracts Critical
Summaries Ethical Moment News Health Policy Perspectives For the Dental Patient Supplements
Government-funded articles published more than 12 months previous and back to 2000 3. All non-
members and non-JADA subscribers must pay an access fee per article for all articles not listed in
item 2 above.
Reprinting of material published in JADA
All accepted manuscripts and their accompanying illustrations become the permanent property of
the American Dental Association, owner and publisher of JADA, and may not be published elsewhere
in full or in part, in print or electronically, without written permission from the American Dental
Association. Any party seeking individual or multiple copies of material published in JADA must
request permission from Elsevier's Global Rights Department in Oxford, UK. Phone: 1-215-239-3804
or +44 (0) 1865 843830; fax: +44 (0) 1865 853333. Requests may also be completed online via the
Elsevier homepage (http://elsevier.com/authors/obtaining-permission-to-re-use-elsevier-material).
The request must state exactly what material is being borrowed, the issue in which it was published,
the intended use of the material being borrowed, the name of the publication in which the reprinted
material will appear (if applicable), the print quantity of distribution, the audience and whether the
use is for financial gain.
Further guidelines on reprinting are available from the publisher.
Publicity
Any publicity (press releases, press coverage, etc.) about articles published in JADA must
be coordinated through the ADA Public Affairs Department (phone 312.440.2806, email
mediarelations@ada.org).
Author Inquiries
For inquiries relating to the submission of articles (including electronic submission)
please visit this journal's homepage. You may also contact the JADA editorial office at
jadaoffice@ada.org. For detailed instructions on the preparation of electronic artwork, please
visit http://www.elsevier.com/artworkinstructions. Contact details for questions arising after
acceptance of an article, especially those relating to proofs, will be provided by the publisher.
You can track accepted articles at http://www.elsevier.com/trackarticle. You can also check
our Author FAQs at http://www.elsevier.com/authorFAQ and/or contact Customer Support via
http://support.elsevier.com.
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